|
WO2021068953A1
|
|
Substituted tricyclic compound as prmt5 inhibitor and use thereof
|
|
WO2021052307A1
|
|
Anti-b7-h3 antibody and application thereof
|
|
WO2020103817A1
|
|
TGF-βR1 INHIBITOR AND USE THEREOF
|
|
CN111196808A
|
|
Diazabicyclo compounds and their use
|
|
CN111196782A
|
|
Dihydroazepinyl compounds, preparation method and application thereof
|
|
TW202024068A
|
|
Monobactam compounds and use therefor
|
|
CN111138459A
|
|
Optical isomer of FGFR4 inhibitor and application thereof
|
|
CN111100086A
|
|
1,3, 4-oxadiazole-2-cyclobutyl compound and preparation method thereof
|
|
TW202024042A
|
|
1,3,4-oxadiazole-2-cyclobutyl compounds, preparation method therefor and application thereof
|
|
WO2020078402A1
|
|
COMPOUND AS TGF-β R1 INHIBITOR AND APPLICATION THEREOF
|
|
CN110938083A
|
|
Compounds as BACE1 inhibitors and uses thereof
|
|
CN110872350A
|
|
anti-CD 47 antibodies and uses thereof
|
|
TW202023613A
|
|
Anti-claudin182 antibody and use thereof
|
|
CN111484504A
|
|
Optical isomer of ACC inhibitor and application thereof
|
|
CN110054614A
|
|
The officinal salt and preparation method thereof of triazines IDH inhibitor
|
|
CN110054616A
|
|
The preparation method of triazines IDH inhibitor
|
|
CN110054615A
|
|
The crystal form of triazines IDH inhibitor mesylate
|
|
CN110051673A
|
|
A kind of medical composition and its use comprising triazines IDH inhibitor
|
|
CN110054617A
|
|
Compound in triazine class, preparation method and the usage
|
|
CN109705118A
|
|
The preparation method of tricyclic antidepressants EGFR kinase inhibitor
|
